Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
service tags : Ongoing save search
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Published: 2024-04-09 (Crawled : 22:00) - globenewswire.com
ALXO | $12.86 -1.31% -1.32% 330K
|
Commercial Services
|
| O: -2.59%
H: 1.75%
C: 0.25%
ongoing trial
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
CRDF | $5.265 -6.15% -6.55% 650K
|
Health Services
|
| O: 0.85%
H: 5.73%
C: -4.55%
ongoing preclinical meeting study
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm
Published: 2024-03-05 (Crawled : 18:00) - prnewswire.com
LTRX | $3.165 -4.38% -4.58% 210K
|
Distribution Services
|
| O: -0.25%
H: 1.76%
C: -1.01%
IRTC | $109.61 -3.1% -3.2% 340K
|
Health Technology
|
| O: -0.95%
H: 0.8%
C: -0.54%
RILY | $20.33 -4.42% -4.62% 630K
|
Finance
|
| O: -2.88%
H: 13.58%
C: 3.95%
irhythm deadline ongoing
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Instacart
Published: 2024-03-05 (Crawled : 18:00) - prnewswire.com
CART | $37.09 -1.9% -1.94% 3M
|
|
| O: -0.18%
H: 1.58%
C: -2.47%
LTRX | $3.165 -4.38% -4.58% 210K
|
Distribution Services
|
| O: -0.25%
H: 1.76%
C: -1.01%
RILY | $20.33 -4.42% -4.62% 630K
|
Finance
|
| O: -2.88%
H: 13.58%
C: 3.95%
deadline ongoing
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantronix
Published: 2024-03-05 (Crawled : 18:00) - prnewswire.com
LTRX | $3.165 -4.38% -4.58% 210K
|
Distribution Services
|
| O: -0.25%
H: 1.76%
C: -1.01%
IRTC | $109.61 -3.1% -3.2% 340K
|
Health Technology
|
| O: -0.95%
H: 0.8%
C: -0.54%
RILY | $20.33 -4.42% -4.62% 630K
|
Finance
|
| O: -2.88%
H: 13.58%
C: 3.95%
deadline ongoing
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
QNRX | $0.759 2.43% 2.37% 81K
|
Professional, Scientific, and T...
|
| O: 113.71%
H: 4.39%
C: -51.01%
fda clearance ongoing pharmaceuticals
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
SLRX A | $0.499 -0.2% -0.2% 5.7K
|
Commercial Services
|
| O: -0.02%
H: 7.98%
C: -1.93%
review update ongoing seclidemstat trials
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
Published: 2024-02-22 (Crawled : 12:30) - prnewswire.com
ELEV | $4.43 -6.34% -6.77% 610K
|
Professional, Scientific, and T...
|
| O: -1.44%
H: 5.49%
C: -1.1%
eo-3021 first japan ongoing trial
Roth CH Abandons Proposed Reduction in Trust Contribution for Ongoing Extensions
Published: 2023-12-20 (Crawled : 14:30) - spacfeed.com
NBR | $78.24 -1.45% 0.0% 150K
|
Industrial Services
|
| O: 0.34%
H: 1.22%
C: -3.61%
ongoing trust
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219
Published: 2023-12-11 (Crawled : 16:00) - biospace.com/
BMEA | $12.53 -3.47% -3.59% 710K
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 study
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
Published: 2023-12-11 (Crawled : 14:30) - globenewswire.com
BMEA | $12.53 -3.47% -3.59% 710K
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 meeting leukemia study
EHANG ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In EHang To Contact Him Directly To Discuss Their Options
Published: 2023-12-10 (Crawled : 00:00) - prnewswire.com
EH | $16.37 -3.08% -3.18% 1.5M
|
Technology Services
|
| O: 0.36%
H: 3.75%
C: 1.69%
deadline ongoing
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | $3.95 1.78% 6.6K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular
FARFETCH ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Farfetch To Contact Him Directly To Discuss Their Options
Published: 2023-12-10 (Crawled : 16:20) - prnewswire.com
PAYC 4 | $192.73 -2.66% 0.0% 600K
|
Technology Services
| Email alert
Add to watchlist
FTCH | $0.6428 -13.26% -34.66% 0
|
Technology Services
| Email alert
Add to watchlist
deadline ongoing
FISKER ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fisker To Contact Him Directly To Discuss Their Options
Published: 2023-12-10 (Crawled : 16:20) - prnewswire.com
FSR | $0.0896 0.0% 62M
|
Finance
| Email alert
Add to watchlist
PAYC 4 | $192.73 -2.66% 0.0% 600K
|
Technology Services
| Email alert
Add to watchlist
FTCH | $0.6428 -13.26% -34.66% 0
|
Technology Services
| Email alert
Add to watchlist
deadline ongoing
ADOBE ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Adobe To Contact Him Directly To Discuss Their Options
Published: 2023-12-10 (Crawled : 16:20) - prnewswire.com
ADBE | $470.17 -0.83% -0.83% 3.4M
|
Technology Services
| Email alert
Add to watchlist
DMTK 4 | $0.62 -0.32% -0.32% 100K
|
Health Technology
| Email alert
Add to watchlist
CGRNQ 4 | $0.21 46.43% 5.7K
|
n/a
| Email alert
Add to watchlist
deadline ongoing
DERMTECH ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options
Published: 2023-12-10 (Crawled : 16:20) - prnewswire.com
ADBE | $470.17 -0.83% -0.83% 3.4M
|
Technology Services
| Email alert
Add to watchlist
DMTK 4 | $0.62 -0.32% -0.32% 100K
|
Health Technology
| Email alert
Add to watchlist
CGRNQ 4 | $0.21 46.43% 5.7K
|
n/a
| Email alert
Add to watchlist
deadline ongoing
BEAUTY HEALTH ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Beauty Health To Contact Him Directly To Discuss Their Options
Published: 2023-12-10 (Crawled : 16:20) - prnewswire.com
SKIN | $3.57 -2.46% -2.52% 2.2M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
DMTK 4 | $0.62 -0.32% -0.32% 100K
|
Health Technology
| Email alert
Add to watchlist
CGRNQ 4 | $0.21 46.43% 5.7K
|
n/a
| Email alert
Add to watchlist
health deadline ongoing beauty
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes
Published: 2023-12-08 (Crawled : 15:30) - biospace.com/
BMEA | $12.53 -3.47% -3.59% 710K
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 10.15%
C: 8.48%
alent-111 control treatment ongoing bmf-219 diabetes study
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-12-08 (Crawled : 14:00) - globenewswire.com
BMEA | $12.53 -3.47% -3.59% 710K
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 10.15%
C: 8.48%
alent-111 disease congress control world presentation treatment ongoing bmf-219 diabetes cardiovascular insulin study
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.